Any toxicity that is at least possibly related to the study drug may be considered as a DLT, which is defined as non-acceptable (as defined below) treatment related toxicity (i.e., not attributable to the active disease, disease -related processes under investigation or intercurrent illness) observed during the first 4 weeks (or Cycle 1 a nd Cycle 2) of study treatment. Ongo ing safety events beyond Cycle 2 will be reviewed across all cohorts during the study to help inform dose escalation decisions. Note, that all patients who enrolled in the study will be included in assessment of DLT. DLT is defined as non -acceptable toxicity which includes : 1. Hematological toxicities ≥ Grade 3. 2. Non -hematological toxicity ≥ Grade 3. 3. Autoimmunity ≥ Grade 3 4. Any other toxicity (greater than at baseline), considered clinically significant and/or unacceptable, and that does not respond to supportive care and results in a disruption of the dosing schedule of more than 14 days. DLT excludes: 1. Hematological and non -hematological ≤ Grade 2 unless considered non-acceptable . 2. Grade 3 self -limited or medically controllable toxicities (e.g., fever without ≥ Grade 3 neutropenia, nausea, vomiting, diarrhea, fatigue). 3.